Source: Annual Congress 2003 - Newer and alternative non-steroidal treatments for asthmatic inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Djukanovic, S. J. Wilson, M. Kraft, N. Jarjour, M. Steel, F. K. Chung, W. Bao, A. Fowler Taylor, J. Mathews, W. W. Busse, S. T. Holgate, J. V. Fahy (Southampton, United Kingdom). Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma. Eur Respir J 2003; 22: Suppl. 45, 1391

Member's Comments

No comment yet.

Related content which might interest you: The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001 Induction of allergic bronchial hyperreactivity in DA-rats despite low-level eosinophilia in airways and lack of specific IgE antibodies Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007 Effects of anti-IgE on asthma exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 12s Year: 2003 Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Targeting atopic inflammation: anti-IgE treatment Source: Annual Congress 2007 - Novel therapies for severe asthma Year: 2007 The impact of anti-IgE treatment on the airway microbiome in asthma. Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Comparison of anti-IL-9 and anti-IL-5 treatment efficacy in a mouse model of airway eosinophilic inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 482s Year: 2003 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Effect of an inhaled alpha4-antagonist on the allergen-induced late asthmatic response in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005 Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011